The current stock price of TWST is 28.56 USD. In the past month the price decreased by -16.27%. In the past year, price decreased by -32.37%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 25 | 417.40B | ||
| AMGN | AMGEN INC | 15.43 | 181.72B | ||
| GILD | GILEAD SCIENCES INC | 15.46 | 157.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.58 | 109.42B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.79 | 80.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 855.65 | 57.20B | ||
| INSM | INSMED INC | N/A | 42.01B | ||
| NTRA | NATERA INC | N/A | 31.65B | ||
| BIIB | BIOGEN INC | 10.47 | 25.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.99 | 21.48B | ||
| INCY | INCYTE CORP | 15.9 | 19.93B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.10B |
Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. The company is headquartered in South San Francisco, California and currently employs 923 full-time employees. The company went IPO on 2018-10-31. The firm's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. The company has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The firm also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The firm's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. The company has minority ownership in Atlas Data Storage, Inc.
TWIST BIOSCIENCE CORP
681 Gateway Blvd.
South San Francisco CALIFORNIA 94080 US
CEO: Emily M. Leproust
Employees: 923
Phone: 18007190671
Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. The company is headquartered in South San Francisco, California and currently employs 923 full-time employees. The company went IPO on 2018-10-31. The firm's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. The company has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The firm also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The firm's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. The company has minority ownership in Atlas Data Storage, Inc.
The current stock price of TWST is 28.56 USD. The price increased by 9.55% in the last trading session.
TWST does not pay a dividend.
TWST has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
16 analysts have analysed TWST and the average price target is 39.59 USD. This implies a price increase of 38.63% is expected in the next year compared to the current price of 28.56.
The outstanding short interest for TWIST BIOSCIENCE CORP (TWST) is 17.8% of its float.
ChartMill assigns a technical rating of 1 / 10 to TWST. When comparing the yearly performance of all stocks, TWST is a bad performer in the overall market: 79.51% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to TWST. TWST has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months TWST reported a non-GAAP Earnings per Share(EPS) of -2.11. The EPS increased by 41.39% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.24% | ||
| ROE | -17.81% | ||
| Debt/Equity | 0 |
16 analysts have analysed TWST and the average price target is 39.59 USD. This implies a price increase of 38.63% is expected in the next year compared to the current price of 28.56.
For the next year, analysts expect an EPS growth of 26.72% and a revenue growth 16.18% for TWST